EVI makes a full kit of patent pending devices to enable vascular surgeons to treat the most difficult patients with advanced PAD, who have no good current treatment. An experienced management team is ready to lead the company through the short 510K FDA approval cycle and into the market, with possible exit in less than 2 years once 510K is obtained. Over 150 patients of data confirm results for this late stage deal at an early stage valuation.